Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07334886 · ClinicalTrials.gov registry record · Phase 1

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

A Phase 1 study, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target

NCT07334886 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07334886, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target

Study Summary

The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.

Interventions

  • DRUG [14C]Ulonivirine

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-09-17
Est. Completion 2025-11-11
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

What the Registry Record Tells You About NCT07334886

The ClinicalTrials.gov registry entry for NCT07334886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which [14C]Ulonivirine is the first listed.

NCT07334886 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07334886 about?

NCT07334886 is a clinical study titled "A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)". The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.

What is the current status of trial NCT07334886?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-09-17. Estimated completion is 2025-11-11.

What interventions are being tested in trial NCT07334886?

The interventions under investigation include: [14C]Ulonivirine (DRUG).

Who is sponsoring clinical trial NCT07334886?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.